Abstract:Objectives: Teicoplanin has been extensively used in the treatment for infections caused by gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). However, current teicoplanin treatment is challenging due to relatively low and variable concentrations under standard dosage regimens. This study aimed to investigate the population pharmacokinetics (PPK) characteristics of teicoplanin in adult sepsis patients and provide recommendations for optimal teicoplanin dosing regimens. Methods: A total of 249 serum concentration samples from 59 septic patients were prospectively collected in the intensive care unit (ICU). Teicoplanin concentrations were detected, and patients' clinical data were recorded. PPK analysis was performed using a non-linear, mixed-effect modeling approach. Monte Carlo simulations were performed to evaluate currently recommended dosing and other dosage regimens. The optimal dosing regimens were defined and compared by different pharmacokinetic/pharmacodynamic parameters, including trough concentration (C min ), the ratio of 24-h area under the concentration-time curve to the minimum inhibitory concentration (AUC 0-24 /MIC), as well as the probability of target attainment (PTA) and the cumulative fraction of response (CFR) against MRSA. Results: A two-compartment model adequately described the data. The final model parameter estimates for clearance, central compartment volume of distribution, intercompartmental clearance and peripheral compartment volume were 1.03 L/h, 20.1 L, 3.12 L/h and 101 L, respectively. Glomerular filtration rate (GFR) was the only covariate that significantly affected teicoplanin clearance. Model-based simulations revealed that 3 or 5 loading doses of 12/15 mg/kg every 12 h followed by a maintenance dose of 12/15 mg/kg every 24 h–72 h for patients with different renal functions were required to achieve a target C min of 15 mg/L and a target AUC 0-24 /MIC of 610. For MRSA infections, PTAs and CFRs were not satisfactory for simulated regimens. Prolonging the dosing interval may be easier to achieve the target AUC 0-24 /MIC than reducing the unit dose for renal insufficient patients. Conclusion: A PPK model for teicoplanin in adult septic patients was successfully developed. Model-based simulations revealed that current standard doses may result in undertherapeutic C min and AUC, and a single dose of at least 12 mg/kg may be needed. AUC 0-24 /MIC should be preferred as the PK/PD indicator of teicoplanin, if AUC estimation is unavailable, in addition to routine detection of teicoplanin C min on Day 4, follow-up therapeutic drug monitoring at steady-state is recommended.

Pharmacoeconomic evaluation of imipenem for anti-postoperative infection based on Monte Carlo simulation

Pharmacokinetic/Pharmacodynamic Analysis Of Imipenem In Plasma And Peritoneal Liquid In Chinese Patients With Perforated Upper Gastrointestinal Tract

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

Study on the antibacterial activity of three carbapenems to the strains isolated from ICU

Use of Monte Carlo Simulation to Estimate and Optimize Treatment Regimens for Antibiotic Administration in General Surgery

Effectiveness of Continuous Improvement by a Clinical Pharmacist-Led Guidance Team on the Prophylactic Antibiotics Usage Rationality in Intervention Procedure at a Chinese Tertiary Teaching Hospital

Multicenter Randomized Controlled Clinical Trial on Teicoplanin Versus Vancomycin

PMU28 CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA

Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused by Escherichia Coli and Klebsiella Pneumoniae: A Multicenter Study in China

Evaluation of Biapenem Regimens in Treatment of Gram-Negative Bacterial Infections with Monte Carlo Simulation

PP118 the Value of New Antibiotic Treatment Strategies in Zhejiang Province, China

Multiple measures to improve perioperative antimicrobial use in typeⅠin-cision operation

OP115 Effect of Multiple Drug Resistance on Costs for Patients with Intra-Abdominal Infections in China

Pharmacist Interventions for Prophylactic Antibiotic Use in Urological Inpatients Undergoing Clean or Clean-Contaminated Operations in a Chinese Hospital

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis

Analysis of the Improvement of Perioperative Antibiotic Prophylaxis in Our Hospital

Pharmacodynamic Target Attainment of Seven Antimicrobials Against Gram-negative Bacteria Collected from China in 2003 and 2004.

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against <i>Enterobacteriaceae</i>

Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients

The Value of Given Antibiotics Rationally during the Perioperation in Orthopaedics